Drug companies confident Medicare price deals won't hit bottom lines

Top executives of drug companies suing to stop the Biden administration's Medicare price negotiation law are telling shareholders and analysts the final price offers won't materially impact their companies' respective bottom lines. The comments from executives of companies including Pfizer, Bristol Myers Squibb, Johnson & Johnson and AbbVie suggest the price cuts won't be as...